Strategic Planning Group LLC Sells 1,144 Shares of Solventum Co. (NYSE:SOLV)

Strategic Planning Group LLC lowered its position in Solventum Co. (NYSE:SOLV) by 16.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,762 shares of the company’s stock after selling 1,144 shares during the period. Strategic Planning Group LLC’s holdings in Solventum were worth $381,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Modus Advisors LLC purchased a new stake in Solventum in the 4th quarter valued at about $25,000. Copeland Capital Management LLC purchased a new stake in shares of Solventum during the third quarter valued at approximately $26,000. Mather Group LLC. bought a new stake in Solventum during the third quarter worth $27,000. True Wealth Design LLC boosted its position in Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after purchasing an additional 471 shares during the last quarter. Finally, NCP Inc. bought a new position in Solventum in the 2nd quarter valued at $35,000.

Solventum Trading Down 0.6 %

NYSE:SOLV opened at $74.44 on Thursday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock has a fifty day moving average of $69.87 and a 200 day moving average of $66.92. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.15 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.23). The company had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.05 billion. On average, equities analysts forecast that Solventum Co. will post 6.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on SOLV. Stifel Nicolaus began coverage on shares of Solventum in a research note on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price on the stock. Morgan Stanley boosted their target price on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Mizuho initiated coverage on Solventum in a report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective for the company. Finally, Piper Sandler lifted their target price on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.